AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$ERAS

Erasca, Inc.

Price · $ERASvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ERAS in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ERAS in the last 30 days.

Top stories · $ERASMore →
MAY 12·Stock TitanMed

Erasca (NASDAQ: ERAS) deepens RAS pipeline, takes $150M R&D charge in Q1

Erasca announced a Q1 2026 net loss of $183.4 million, primarily due to a $150 million in-process R&D expense to secure worldwide rights for ERAS-0015. Despite this, the company ended the quarter with $408.5 million in cash, projecting funding into the second half of 2028, and advanced its RAS-targeting pipeline with new collaborations and patent issuances. Key milestones include upcoming data readouts for ERAS-0015 and ERAS-4001 clinical trials.

MAY 11·Investing.com Nigeria

Erasca stock jumps on Merck cancer drug trial collaboration By Investing.com

Erasca Inc. (NASDAQ:ERAS) shares surged after announcing a clinical trial collaboration with Merck. The agreement involves Erasca conducting the AURORAS-1 study, evaluating its ERAS-0015 in combination with Merck’s KEYTRUDA for RAS-mutant solid tumors, with Merck supplying the drug at no cost. This collaboration aims to improve treatment outcomes for RAS-driven cancers, which affect millions globally, by potentially counteracting immunosuppression and resistance mechanisms.

MAY 11·Seeking Alpha

Erasca teams up with Merck to test ERAS-0015 with Keytruda, shares jump (MRK:NYSE)

Erasca has announced a clinical trial collaboration and supply agreement with Merck to evaluate its pan-RAS inhibitor, ERAS-0015, in combination with Merck's Keytruda. The agreement supports the AURORAS-1 study, a clinical proof-of-concept trial. Following the announcement, Erasca's shares experienced an approximate 8% jump in early trading.

News on $ERAS

All news →